bispecific antibodies in multiple myeloma: their current role and the future
Published 1 month ago • 98 plays • Length 3:37Download video MP4
Download video MP3
Similar videos
-
3:07
advice for community hematologists when prescribing bispecific antibodies for multiple myeloma
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
1:42
how to best sequence bispecific antibodies and car-t therapy in multiple myeloma
-
1:40
current & future outlooks on car-t therapy & bispecific antibodies in follicular lymphoma
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
1:53
infections following anti-bcma bispecific antibodies for multiple myeloma
-
19:39
t-cell engagers: targets, challenges and opportunity
-
43:38
webinar - bispecific antibodies: the next generation of antibody therapeutics
-
4:31
all you want to know about ablynx's nanobodies
-
1:38
the standard of care in multiple myeloma & emerging treatment options
-
7:05
developments in the use of bispecific antibodies in myeloma and challenges in this space
-
1:56
the future of bispecific antibodies in the treatment and management of r/r follicular lymphoma
-
4:26
antibodies in multiple myeloma and their impact on treatment
-
6:35
the benefits of bispecific antibodies for treating multiple myeloma
-
0:41
fcrh5 & gprc5d bispecific antibodies: antigen targets beyond bcma for multiple myeloma
-
23:13
bispecific antibodies in multiple myeloma | dana-farber cancer institute
-
4:17
the evolving role of autosct in the age of car-t for multiple myeloma: current & future perspectives
-
2:56
the exciting future of bispecific antibodies
-
1:19
infectious toxicities in patients with multiple myeloma treated with bispecific antibodies
-
2:22
immuno-oncology and the future of multiple myeloma treatment